◆英語タイトル:Lin Bioscience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11120
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Lin Bioscience Inc (Lin Bioscience) is a drug development company that specializes in developing therapies for oncology, ophthalmology and other metabolic diseases. The company’s pipeline product LBS-008 is an oral therapy for treatment of macular degeneration; LBS-007 is a small molecular inhibitor for treatment of cancer, and LBS-002 is an anti tubulin for the treatment of primary and metastatic brain tumors. Its pipeline products aim to find therapies for AMDStargardt disease, acute leukemia solid tumors, triple negative breast cancer and glioblastomabrain metastasis. Lin Bioscience is headquartered in Taipei City, Taiwan.
Lin Bioscience Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lin Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 7
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 9
Licensing Agreements 9
Lin BioScience Enters into Licensing Agreement with University of Sydney 9
Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 10
Lin Bioscience Enters into Licensing Agreement with Columbia Technology Ventures 11
Lin Bioscience Inc – Key Competitors 12
Lin Bioscience Inc – Key Employees 13
Lin Bioscience Inc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Recent Developments 15
Product Approvals 15
Sep 18, 2018: FDA grants Lin BioScience Rare Pediatric Disease status for LBS-008 to treat Stargardt Disease 15
Jun 27, 2018: Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease 16
Clinical Trials 17
Oct 26, 2017: Lin BioScience Receives US FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18
List of Tables
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lin Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lin Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 7
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Lin BioScience Enters into Licensing Agreement with University of Sydney 9
Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 10
Lin Bioscience Enters into Licensing Agreement with Columbia Technology Ventures 11
Lin Bioscience Inc, Key Competitors 12
Lin Bioscience Inc, Key Employees 13
Lin Bioscience Inc, Other Locations 14
List of Figures
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lin Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 7